CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Update

CytomX Therapeutics, Inc. (NASDAQ:CTMX) was the target of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 5,670,000 shares, a decrease of 6.6% from the October 15th total of 6,070,000 shares. Based on an average daily trading volume, of 767,300 shares, the days-to-cover ratio is currently 7.4 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CTMX. SG Americas Securities LLC bought a new stake in shares of CytomX Therapeutics during the first quarter worth approximately $57,000. US Bancorp DE bought a new stake in CytomX Therapeutics in the 3rd quarter valued at $40,000. XTX Topco Ltd increased its position in CytomX Therapeutics by 382.6% during the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after buying an additional 48,033 shares during the period. Forefront Analytics LLC increased its position in CytomX Therapeutics by 206.7% during the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock worth $78,000 after buying an additional 43,176 shares during the period. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of CytomX Therapeutics by 96.6% during the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after buying an additional 40,309 shares in the last quarter. Institutional investors and hedge funds own 67.77% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a report on Monday, November 11th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, CytomX Therapeutics currently has a consensus rating of “Hold” and an average target price of $5.77.

CytomX Therapeutics Price Performance

CytomX Therapeutics stock opened at $0.86 on Tuesday. The firm has a market capitalization of $67.55 million, a P/E ratio of 5.08 and a beta of 1.06. The stock has a fifty day moving average price of $1.11 and a two-hundred day moving average price of $1.40. CytomX Therapeutics has a 52-week low of $0.84 and a 52-week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The business had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. During the same period last year, the business posted $0.04 earnings per share. On average, equities research analysts predict that CytomX Therapeutics will post -0.13 EPS for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.